Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials

Cady, Roger; Sheftell, Fred D.; Lipton, Richard B.; O’Quinn, Stephen; Jones, Martin; Putnam, D. Gayla; Crisp, Adam; Metz, Alan; McNeal, Scott

doi:10.1016/s0149-2918(00)80083-1

Cited by 206 publications

(207 citation statements)

References 7 publications

Supporting

Mentioning

202

Contrasting

Order By: Relevance

“…The results of this study suggest that the greater the intensity of pain at onset of the attacks, the sooner the attack is treated. Clinical studies have shown that treating a migraine early, while pain is mild, results in the best response to therapy [12][13][14]. Data reported by Klapper et al demonstrated the efficacy of zolmitriptan conventional tablets, taken while headache pain was mild, in terms of headache response and reduction in progression to more severe pain intensity [15].…”

Section: Discussionmentioning

confidence: 99%

Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study

et al. 2005

View full text Add to dashboard Cite

In phase one of the REALIZE study, zolmitriptan nasal spray demonstrated a significant headache response from 10 min post–dose and total symptom relief from 30 min post–dose. The objective of phase two was to investigate patients' dosing patterns, satisfaction and preference following openlabel treatment with the nasal spray. Up to 3 attacks were treated. The ITT population consisted of 851 patients. The median time from onset of symptoms to treatment was 1 h 15 min (primary endpoint). Most patients reported being satisfied or very satisfied with zolmitriptan nasal spray (75.7%). Furthermore, the majority of patients would be willing to use zolmitriptan nasal spray in the future (59.8%) and preferred zolmitriptan nasal spray over previous therapies (57.8%). Zolmitriptan nasal spray was well tolerated. Most patients were satisfied with zolmitriptan nasal spray, were willing to continue using it and preferred it to previous therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…A retrospective subgroup analysis performed on protocol violators in a migraine trial suggested that sumatriptan is most effective in relieving migraine pain when treatment is initiated at an earlier, mild stage of migraine pain. 13 Recent clinical trials have demonstrated similar results with sumatriptan 14,15 and other triptans. 16,17 The present study was conducted in order to augment the evidence supporting the early treatment of migraine pain with sumatriptan.…”

mentioning

confidence: 82%

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

Jelinski

Becker²,

Christie³

et al. 2006

Can J Neurol Sci.

View full text Add to dashboard Cite

Migraine is a common neurological disorder that is characterized by episodic headaches associated with symptoms such as nausea, visual disturbances, photophobia, and phonophobia. In Canada, approximately 7% of adult males and 22% of adult females suffer from migraine. 1 Migraine symptoms result in a considerable burden with regard to health care utilization, health care costs, and work/productivity loss due to disability and decreased functional status. [2][3][4][5][6] Clinical trials have demonstrated that sumatriptan (Imitrex®, GlaxoSmithKline) is effective in relieving migraine pain. These studies have established the efficacy of sumatriptan among patients who treated their migraines at a point in which their headache pain was classified as moderate or severe. 7-11 However, ABSTRACT: Background: There is evidence that headache response rates may be higher if triptans are used early when a migraine attack is still mild, as compared to when it is treated after pain has reached moderate or severe intensity. Methods: In this randomized, double blind, placebo controlled, parallel group clinical trial, 361 patients took either placebo, sumatriptan 50 mg, or sumatriptan 100 mg in a single attack study. The primary outcome measure was pain-free status at two hours. Results: In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p<0.001, active treatment groups vs. placebo). Conclusions: Both sumatriptan 50 mg and 100 mg were significantly superior to placebo for the pain-free end point at two hours. The pain-free response rates in this trial where sumatriptan was taken while the headache was still mild were generally higher than in older clinical trials where headache was treated after reaching a moderate or severe intensity. RÉSUMÉ: Absence de douleur comme mesure de l'efficacité du sumatriptan pour le traitement précoce de la migraine. Contexte: Le taux de réponse serait plus élevé si les triptans sont utilisés tôt au cours d'une crise de migraine alors que les symptômes sont légers plutôt que quand la douleur est devenue modérée ou sévère. Méthodes: Il s'agit d'une étude de pharmacologie clinique randomisée, à double insu, avec placebo et groupes parallèles. 361 patients ont pris soit le placebo, le sumatriptan 50 mg ou le sumatriptan 100 mg au cours d'une seule crise migraineuse. Le critère d'évaluation primaire était l'absence de douleur 2 heures après la prise du médicament. Résultats: À l'analyse selon l'intention de traitement, le taux de patients sans douleur était de 16%, 40% et 50% pour le groupe placebo, le groupe sumatriptan 50 mg et le groupe sumatriptan 100 mg respectivement (groupes traitement actif versus placebo, p > 0,001). Conclusions: Le sumatriptan 50 mg et 100 mg étaient significativement supérieurs au placebo quant au critère d'évaluation primaire, soit l'absence de douleur 2 heures après la prise du médicament. Le taux de réponse, soit l'absence de douleur, dans cette étude ...

show abstract

“…Clinical research has shown that treating a migraine attack early, while headache pain is still mild, results in the best response to therapy [18][19][20] . The importance of early treatment was emphasised in a study in which 280 patients with disabling migraine treated an attack during the mild phase (within 4 hours of onset) with conventional oral placebo or zolmitriptan tablets 21 .…”

Section: Facilitation Of Early Treatmentmentioning

confidence: 99%

Part I: What do patients really need and want from migraine treatment?

Gendolla

2005

Current Medical Research and Opinion

View full text Add to dashboard Cite

addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability addition to migraine impairing a patient's ability to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of to function normally during an attack, fear of the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life the next attack can detract from quality of life between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who between attacks. Of those migraineurs who consult a physician for headache, the minority are consult ...

show abstract

Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials

Cited by 206 publications

References 7 publications

Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study

Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

Part I: What do patients really need and want from migraine treatment?

Contact Info

Product

Resources

About